For The Latest Medical News, Health News, Research News, COVID-19 News, Pharma News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Thailand Cannabis News, Cancer News, Doctor News, Thailand Hospital News, Oral Cancer News, Thailand Doctors

BREAKING NEWS
Source: SARS-CoV-2 Induced Autoantibodies  Feb 01, 2022  3 years, 6 months, 2 weeks, 6 days, 14 hours, 55 minutes ago

BREAKING! French Study Discovers That Autoantibodies Neutralizing Type I Interferons Found Responsible For 20 Percent Of All COVID-19 Deaths!

2872 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
BREAKING! French Study Discovers That Autoantibodies Neutralizing Type I Interferons Found Responsible For 20 Percent Of All COVID-19 Deaths!
Source: SARS-CoV-2 Induced Autoantibodies  Feb 01, 2022  3 years, 6 months, 2 weeks, 6 days, 14 hours, 55 minutes ago
French researchers from Robert Ballanger Hospital-France, Necker Hospital for Sick Children-France and University of Paris have in a new study found that that autoantibodies neutralizing type 1 interferons found responsible for 20 percent of all local COVID-19 deaths!


 
The study findings shocking also found persistence of neutralizing Auto-Abs almost 1 year after COVID-19 infection in certain patients. Risk associated with this persistence is not known to date but must be explored, especially given the potential impact of these auto-Abs on the severity of other viral diseases, as described for adverse reactions following yellow-fever vaccination.
 
The study team aimed to assess the prevalence and clinical impact of the auto-Abs to type I IFNs in the Seine-Saint-Denis district, which was one of the most affected areas by COVID-19 in France during the first wave.
 
The study team tested for the presence of auto-Abs neutralizing type I IFNs in a cohort of patients admitted for critical COVID-19 pneumonia during the first wave in the spring of 2020 in the medicine departments at Robert Ballanger Hospital, Aulnay sous Bois.
 
The team found circulating auto-Abs that neutralized 100 pg/mL IFN-α2 and/or IFN-ω in the plasma (diluted 1/10) of 7.9% (11 of 139) of the patients hospitalized for critical COVID-19.
 
The presence of neutralizing auto-Abs was associated with an increased risk of mortality, as these auto-Abs were detected in 21% of patients who died from COVID-19 pneumonia. Deceased patients with and without auto-Abs did not present overt clinical differences.
 
The study findings confirmed both the importance of type I IFN immunity in host defense against SARS-CoV-2 infection and the usefulness of detection of auto-Abs neutralizing type I IFNs in the management of patients.
 
The study findings were published in the peer reviewed Journal of Clinical Immunology. https://link.springer.com/article/10.1007/s10875-021-01203-3
 
Numerous recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) in at least 15% of patients with critical COVID-19 pneumonia. https://www.science.org/doi/10.1126/science.abd4585
 
Shockingly in another study, these auto-Abs were found in almost 20% of deceased patients across all ages. https://www.science.org/doi/10.1126/sciimmunol.abl4340
 
Past studies showed that patients with neutralizing auto-Abs against type I IFNs were typically mostly men (94%) and that half were older than 65 years.
https://www.science.org/doi/10.1126/science.abd4585
 
It was also recently shown that proportion of patients with critical COVID-19 having neutralizing auto-Abs increased with age. https://www.science.org/doi/10.1126/sciimm unol.abl4340
 
In this study, although differences were not significant with regard to the patients without neutralizing auto-Abs, most of patients (82%) with neutralizing auto-Abs were men and over the age of 65 years.
 
The full engagement status was significantly less frequent in patient with auto-Abs than in patients without auto-Abs but like other studies, there was no difference for comorbidities. https://pubmed.ncbi.nlm.nih.gov/33851338/
https://onlinelibrary.wiley.com/doi/10.1002/cti2.1327
 
It was also found that there was a significant correlation between the presence of auto-Abs neutralizing type I IFNs, raised levels of C-protein reactive, and low lymphocytes counts was observed, in this current study, no difference was seen for these biological characteristics.
 
The study findings found that neutralizing antibodies against type I INFs was described in almost all of patients with auto immune polyendocrinopathy syndrome type I and also in patients with thymoma, myasthenia gravis and systemic lupus erythematosus.
 
These autoimmune diseases were not described in patients with neutralizing auto-Abs, although 2 of 11 (18%) patients with neutralizing Auto-Abs against type I IFNs had a history of psoriasis. Research of antinuclear antibodies (ANA) did not reveal high titer of ANA in the 6 patients that were analyzed.
 
The study found that the presence of neutralizing auto-Abs was associated with a more frequent mortality. Up to 21% of patients who died of COVID-19 pneumonia in the study had auto-Abs capable of neutralizing 100 pg/mL type I IFNs in plasma 1/10. Deceased patients with auto-Abs did not present overt clinical differences with deceased patients without auto-Abs.
 
The study findings confirm importance of the IFN-I pathway in the defense against SARS-CoV-2 infection.
 
The detection of neutralizing Auto-Abs against type I IFNs is therefore important due to clinical applications, notably therapeutics. All COVID-19 patients should be screened for these autoantibodies in order to predict which patients infected by SARS-CoV-2 are at higher risk of life-threatening COVID-19. Moreover, early identification of COVID-19 patients with auto-Abs should prompt early treatment and preventive management.
 
The study findings alarmingly also found persistence of neutralizing Auto-Abs almost 1 year after COVID-19 infection in two patients. Risk associated with such persistence is not known to date but warrants urgent research, especially given the potential impact of these auto-Abs on the severity of other viral diseases, as described for adverse reactions following yellow-fever vaccination. https://rupress.org/jem/article/218/4/e20202486/211761/Auto-antibodies-to-type-I-IFNs-can-underlie
 
The study team also stressed, “As high titers auto-Abs against IFN-2 in ELISA are well correlated with neutralizing activity of auto-Abs, such commercial ELISA should be used to detect easily, in routine clinical practice, neutralizing anti IFN-2 auto-Abs. Nevertheless, to our knowledge, no commercial ELISA exists to detect anti IFN- auto-Abs. It would be necessary to complete detection of anti IFN-2 auto-Abs with a functional evaluation of neutralizing anti IFN- auto-Abs, notably if low IFN-2 auto-Abs levels or no IFN-2 auto-Abs are detected.”
 
For more about SARS-CoV-2 Induced Autoantibodies, keep on logging to Thailand Medical News.
 

MOST READ

Aug 12, 2025  10 days ago
Nikhil Prasad
Aug 09, 2025  13 days ago
Nikhil Prasad
Aug 07, 2025  15 days ago
Nikhil Prasad
Jul 31, 2025  22 days ago
Nikhil Prasad
Jul 29, 2025  24 days ago
Nikhil Prasad
Jul 21, 2025  1 month ago
Nikhil Prasad
Jul 19, 2025  1 month ago
Nikhil Prasad
Jul 17, 2025  1 month ago
Nikhil Prasad
Jul 15, 2025  1 month ago
Nikhil Prasad
Jul 14, 2025  1 month ago
Nikhil Prasad
Jun 28, 2025  2 months ago
Nikhil Prasad
May 10, 2025  3 months ago
Nikhil Prasad
Apr 29, 2025  4 months ago
Nikhil Prasad